EU industry still unhappy over PV fee burden as legislation nears approval
This article was originally published in Scrip
European industry bodies have generally welcomed last week's compromise deal on the new fees for pharmacovigilance activities, but are disappointed that the fee level for safety referrals is significantly higher than originally proposed by the European Commission. They are also concerned that industry is being asked to share the whole burden of funding the EU's new pharmacovigilance activities.
Register for our free email digests: